Support for use of alpha blockers

Latest research and happenings
Post Reply
User avatar
webslave
Maintenance
Maintenance
Posts: 11390
Joined: Wed Oct 30, 2002 3:18 pm
Location: Please give your location so we can help better
Contact:

Support for use of alpha blockers

Post by webslave »

Eur Urol. 2007 Apr;51(4):1113-1118. Epub 2006 Oct 17

A Placebo-Controlled Comparison of the Efficiency of Triple- and Monotherapy in Category III B Chronic Pelvic Pain Syndrome (CPPS).

Tugcu V, et al. Bakirkoy Teaching Hospital, Istanbul, Turkey.

OBJECTIVES: To perform a prospective, placebo-controlled study to examine the efficacy of alpha-blocker compared with triple therapy (alpha-blocker, anti-inflammatory, and muscle relaxant) in the treatment of Category IIIB chronic pelvic pain syndrome (Category IIIB CPPS).

MATERIALS AND METHODS: The study was conducted between September 2004 and December 2005, and included 90 treatment naive patients, aged 22-42 yr (mean age: 29.1+/-5.2) with Category IIIB CPPS, who were randomized into three groups: group 1, alpha-blocker; group 2, combination of alpha-blocker, anti-inflammatory, and muscle relaxant; group 3, placebo once daily. The patients were treated for 6 mo and were followed up for a further 6 mo. Changes from baseline in the total and domain scores of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) were evaluated. The primary criterion for response was scoring </=2 on the NIH-CPSI quality of life item. The secondary criterion for response was >50% reduction in NIH-CPSI pain score.

RESULTS: The NIH-CPSI initial and sixth-month total scores were 23.1 and 10.7, respectively, in group 1, and 21.9 and 9.2, respectively, in group 2. The initial and sixth-month scores remained stable in group 3 (22.9 and 21.9, respectively). There was no statistically significant difference between two treatment arms with respect to efficiency of treatment (p>0.05). The responses in groups 1 and 2 were found durable at the end of 12 mo.

CONCLUSIONS: We found that alpha-blocker monotherapy was as effective and safe as triple therapy in the treatment of Category IIIB CPPS.

PMID: 17084960 [PubMed - as supplied by publisher]
HAS THIS SITE HELPED YOU?
Say Thanks! by making a small donation
PayPal link at end of page ↓
Please fill out your signature, click here for how to do it
User avatar
webslave
Maintenance
Maintenance
Posts: 11390
Joined: Wed Oct 30, 2002 3:18 pm
Location: Please give your location so we can help better
Contact:

Post by webslave »

Rev Urol. 2006;8(Suppl 4):S26-S34.

Alpha-Blockers for the Treatment of Prostatitis-Like Syndromes.

Nickel JC. Department of Urology, Queen's University Kingston, Ontario, Canada.

Prostatitis is a common medical diagnosis. The etiology of this symptomatic syndrome can be an acute or chronic bacterial infection, a noninfectious initiator (the most common cause), or iatrogenic heat or radiation; the syndrome may coexist with benign prostatic hyperplasia. Alpha-blockers have a role in the treatment of the prostatitis syndromes. In Category I, acute bacterial prostatitis, alpha-blockers have been shown to possibly ameliorate obstructive and irritative voiding symptoms. In Category II, chronic bacterial prostatitis, alpha-blockers seem to reduce the risk of clinical and bacteriological recurrence. In Category III, chronic pelvic pain syndrome, alpha-blockers improve symptoms and quality of life. Alpha-blockers also seem to ameliorate the symptoms and reduce the risk of acute urinary retention in patients who suffer from either heat- or radiation-induced prostatic inflammation. Alpha-blockers improve lower urinary tract symptoms, including pain, in patients who are diagnosed with both prostatitis and benign prostatic hyperplasia. Evidence has proven there is definitely a role for alpha-blockers in the management of the prostatitis syndromes.

PMID: 17215998 [PubMed - as supplied by publisher]
HAS THIS SITE HELPED YOU?
Say Thanks! by making a small donation
PayPal link at end of page ↓
Please fill out your signature, click here for how to do it
Post Reply